Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-24T14:32:28.894Z Has data issue: false hasContentIssue false
  • English
  • Français

New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation

Published online by Cambridge University Press:  04 September 2008

M K J Jaggard ,
C MacRae ,
S Ifeacho ,
S Robinson  and
N S Tolley
M K J Jaggard
Affiliation:
Department of Otolaryngology, St Mary's Hospital, London, UK
C MacRae
Affiliation:
Department of Otolaryngology, St Mary's Hospital, London, UK
S Ifeacho
Affiliation:
Department of Otolaryngology, St Mary's Hospital, London, UK
S Robinson
Affiliation:
Department of Endocrine Medicine, St Mary's Hospital, London, UK
N S Tolley*
Affiliation:
Department of Otolaryngology, St Mary's Hospital, London, UK
*
Address for correspondence: Mr N S Tolley, Department of Otolaryngology, St Mary's Hospital, Imperial College NHS Healthcare Trust, Praed Street, London W2 1NY, UK. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

We report a case of familial medullary thyroid carcinoma in an 87-year-old woman, despite the patient having a high-risk codon 620 mutation.

Method:

Medline and PubMed were searched for cases and literature reviews relating to the following keywords: ‘codon 620’, ‘medullary thyroid carcinoma’, ‘multiple endocrine neoplasia’ and ‘RET proto-oncogene’.

Results:

We report the case of an 87-year-old woman who presented with a goitre, later identified as medullary thyroid carcinoma. Genetic analysis revealed a RET proto-oncogene codon 620 mutation. Genetic testing has revolutionised the management of medullary thyroid carcinoma. The genetic basis of hereditary medullary thyroid carcinoma lies with the RET proto-oncogene. Several disease-causing mutations of this gene have been identified and their clinical prognosis described. The penetrance of these mutations is high; as such, carriers progress to develop medullary thyroid carcinoma at a young age. Mutations at the codon 620 position are classified as high-risk for early development of medullary thyroid carcinoma; thus, the current recommendation is for prophylactic thyroidectomy at five years of age.

Conclusions:

In this case, the progress of hereditary medullary thyroid carcinoma was unique, considering the late presentation of medullary thyroid carcinoma despite the presence of the high-risk RET proto-oncogene codon 620 mutation. The authors wish to highlight the importance of this case, as it may present a counter-argument to the current recommendations for early, prophylactic thyroidectomy in codon 620 mutation carriers in order to prevent early development of medullary thyroid carcinoma.

Keywords

Medullary Thyroid CarcinomaRET Proto-oncogeneMultiple Endocrine NeoplasiaMEN2AMEN2B
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 123 , Issue 7 , July 2009 , pp. 796 - 800
Copyright
Copyright © JLO (1984) Limited 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Hazard, JB, Hawk, WA, Crile, GJ. Medullary (solid) carcinoma of the thyroid: a clinicopathological entity. J Clin Endocrinol Metab 1959;19:152–61Google Scholar
2 Ball, DW, Baylin, SB, De Bustros, AC. Medullary thyroid carcinoma. In: Braverman, LE, Utier, RD, eds. Werner and Ingbar's The Thyroid. Philadelphia: Lippincot Williams & Wilkins, 2000;930–43Google Scholar
3 Easton, DF, Ponder, MA, Cummings, T. The clinical and screening age-at-onset distribution for the MEN-2 syndrome. Am J Hum Genet 1989;44:208–15Google Scholar
4 Mulligan, LM, Kwok, JB, Healey, CS, Eldson, MJ, Eng, C, Gardner, E et al. Germ-line mutations of RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993;363:458–60CrossRefGoogle ScholarPubMed
5 Donis-Keller, H, Dou, S, Chi, D, Carlson, KM, Toshima, K, Lairmore, TC et al. Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 1993;2:851–6CrossRefGoogle ScholarPubMed
6 Schuchardt, A, Dagati, V, Larsson-Blomberg, L, Costantini, F, Pachinis, V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET. Nature 1994;367:380–3CrossRefGoogle ScholarPubMed
7 Frilling, A, Weber, F, Tecklenborg, C, Broelsch, CE. Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene. Langenbecks Arch Surg 2003;388:17–26CrossRefGoogle ScholarPubMed
8 Jing, S, Wen, D, Yu, Y, Holst, PL, Luo, Y, Fang, M et al. GDNF-induced activation of the RET protein tyrosine kinase is mediated by GDNFR-a, a novel receptor for GDNF. Cell 1996;85:1113–24Google Scholar
9 Trupp, M, Arenas, E, Fainzilber, M, Nilsson, AS, Sieber, BA, Grigoriou, M et al. Functional receptor for GDNF encoded by the c-RET proto-oncogene. Nature 1996;381:785–9Google Scholar
10 Wells, SA, Skinner, MA. Prophylactic thyroidectomy based on direct genetic testing, in patients at risk for multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998;106:29–34CrossRefGoogle ScholarPubMed
11 Eng, C. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirchsprung's disease. N Engl J Med 1996;335:943–51CrossRefGoogle Scholar
12 Machens, A, Niccoli-Sire, P, Hoegel, J, Frank-Raue, K, van Vroonhoven, TJ, Roeher, H-D et al. Early malignant progression of hereditary medullary thyroid cancer, for the European Multiple Endocrine Neoplasia (EUROMEN) study group. N Engl J Med 2003;349:1517–25CrossRefGoogle Scholar
13 Mulligan, LM, Eng, C, Attie, T, Lyonnet, S, Marsh, DJ, Hyland, VJ et al. Diverse phenotypes associated with exon 10 mutations of the RET protooncogene. Hum Mol Genet 1994;3:2163–7CrossRefGoogle Scholar
14 Eng, C, Smith, DP, Mulligan, LM, Healey, CS, Zvelebil, MJ, Stonehouse, TJ et al. A novel domain point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995;10:509–13Google Scholar
15 Berndt, I, Reuter, M, Saller, B, Frank-Raue, K, Grussendorf, M, Raue, F et al. A new hot spot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998;83:770–4Google Scholar
16 Bolino, A, Schuffenecker, I, Yin, L, Seri, M, Silengo, M, Tocco, T et al. RET mutations in exon 13 and 14 of FMTC patients. Oncogene 1995;10:2415–19Google Scholar
17 Iwashita, T, Kato, M, Murakami, H, Asai, N, Ishiguro, Y, Ito, S et al. Biological and biochemical properties of RET with kinase domain mutations identified in multiple endocrine neoplasia type 2b and familial medullary thyroid carcinoma. Oncogene 1999;18:3919–22CrossRefGoogle ScholarPubMed
18 Smith, DP, Houghton, C, Ponder, BAJ. Germline mutation of RET codon 883 in two cases of de novo MEN2B. Oncogene 1997;15:1213–17Google Scholar
19 Eng, C, Clayton, D, Schuffenecker, I, Lenoir, G, Cote, G, Gagel, RF et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276:1575–9CrossRefGoogle ScholarPubMed
20 Dralle, H, Gimm, O, Simon, D. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998;22:744–51CrossRefGoogle ScholarPubMed
21 Frank-Raue, K, Buhr, H, Dralle, H. Long-term outcomes in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy. Eur J Endocrinol 2006;155:229–36CrossRefGoogle ScholarPubMed
22 Heshmati, HM, Gharib, H, van Heerden, JA, Sizemore, GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Medicine 1997;103:60–9CrossRefGoogle ScholarPubMed
23 Brandi, ML, Gagel, RF, Angeli, A, Bilezikian, JP, Beck-Peccoz, P, Bordi, C et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658–71CrossRefGoogle ScholarPubMed
24 Yip, L, Cote, GJ, Shapiro, SE, Ayers, GD, Herzog, CE, Sellin, RV et al. Multiple endocrine neoplasia type 2. Arch Surg 2003;138:409–16Google Scholar
25 Machens, A, Dralle, H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 2007;31:957–68CrossRefGoogle ScholarPubMed
26 Skinner, MA, Moley, JF, Dilley, WG, Ozwar, K, Debenedetti, MK, Wells, SA. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005;353:1105–13Google Scholar
27 Gimm, O, Ukkat, J, Niederle, BE. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia. World J Surg 2004;28:257–65CrossRefGoogle ScholarPubMed
28 Machens, A, Holzhausen, HJ, Thanh, PN, Dralle, H. Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers. Surgery 2003;134:425–31Google Scholar
29 Grozinsky-Glasberg, S, Benbassat, CA, Tsvetov, G, Feinmesser, R, Peretz, H, Shimon, I et al. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care centre between 1970 and 2005. Thyroid 2007;17:549–56CrossRefGoogle Scholar